Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Commitment Letter Formalizes REMS Standardization Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.

You may also be interested in...



Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.

FDA Simplifies The Process For REMS Changes

Some typographical changes can be submitted and noted later, according to new draft guidance. Major changes still require pre-approval.

FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance

Meeting with Morquio A patient and caregivers appears to have helped to assuage FDA concerns about clinical relevance of the Vimizim trial’s primary endpoint – and illustrates FDA’s openness to patient input even during specific reviews of new product applications.

Related Content

Topics

UsernamePublicRestriction

Register

PS072752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel